HUE059916T2 - Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére - Google Patents

Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére

Info

Publication number
HUE059916T2
HUE059916T2 HUE19756525A HUE19756525A HUE059916T2 HU E059916 T2 HUE059916 T2 HU E059916T2 HU E19756525 A HUE19756525 A HU E19756525A HU E19756525 A HUE19756525 A HU E19756525A HU E059916 T2 HUE059916 T2 HU E059916T2
Authority
HU
Hungary
Prior art keywords
disorders
treatment
modified
cannabis sativa
substance addiction
Prior art date
Application number
HUE19756525A
Other languages
English (en)
Inventor
Jonnie R Williams
Original Assignee
Mymd Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymd Pharmaceuticals Inc filed Critical Mymd Pharmaceuticals Inc
Publication of HUE059916T2 publication Critical patent/HUE059916T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00Processes for modifying genotypes ; Plants characterised by associated natural traits
    • A01H1/06Processes for producing mutations, e.g. treatment with chemicals or with radiation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/28Cannabaceae, e.g. cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y121/00Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
    • C12Y121/03Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
    • C12Y121/03007Tetrahydrocannabinolic acid synthase (1.21.3.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y121/00Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
    • C12Y121/03Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
    • C12Y121/03008Cannabidiolic acid synthase (1.21.3.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Developmental Biology & Embryology (AREA)
HUE19756525A 2018-02-20 2019-02-11 Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére HUE059916T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862632448P 2018-02-20 2018-02-20

Publications (1)

Publication Number Publication Date
HUE059916T2 true HUE059916T2 (hu) 2023-01-28

Family

ID=67687826

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19756525A HUE059916T2 (hu) 2018-02-20 2019-02-11 Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére
HUE21171866A HUE060229T2 (hu) 2018-02-20 2019-02-11 Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE21171866A HUE060229T2 (hu) 2018-02-20 2019-02-11 Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére

Country Status (13)

Country Link
US (4) US11085047B2 (hu)
EP (2) EP3884936B1 (hu)
JP (2) JP7293561B2 (hu)
KR (2) KR102332631B1 (hu)
CN (2) CN113264914A (hu)
AU (2) AU2019225717B2 (hu)
CA (2) CA3120993C (hu)
ES (2) ES2929366T3 (hu)
HU (2) HUE059916T2 (hu)
IL (2) IL276518B (hu)
PL (2) PL3755318T3 (hu)
PT (2) PT3755318T (hu)
WO (1) WO2019164689A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938547B2 (ja) 2007-05-10 2012-05-23 日本トムソン株式会社 内面シールを備えた直動案内ユニット
WO2022103639A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113099973B (zh) * 2021-05-17 2022-05-27 潍坊市华以农业科技有限公司 一种药用大麻矮化高产的种植方法
EP4436559A1 (en) * 2021-11-27 2024-10-02 Miralogx LLC Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
WO2023150347A2 (en) * 2022-02-07 2023-08-10 Miralogx Llc Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942244A (en) 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
DE102007046086A1 (de) * 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8884100B2 (en) 2009-08-12 2014-11-11 National Research Council Of Canada Aromatic prenyltransferase from Cannabis
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201111261D0 (en) * 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US20160108016A1 (en) * 2012-09-06 2016-04-21 Northeastern University Novel Cannabinergic Compounds and Uses Thereof
CA3130696A1 (en) * 2014-06-27 2015-12-30 National Research Council Of Canada Cannabichromenic acid synthase from cannabis sativa
US20160000843A1 (en) * 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
BR112017015536B1 (pt) * 2015-01-22 2021-05-18 Phytoplant Research S.L métodos de purificação de canabinoides
US20160228385A1 (en) * 2015-02-05 2016-08-11 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US10934554B2 (en) * 2015-05-28 2021-03-02 Tweed, Inc. Cannabis plants having modified expression of THCA synthase
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
AU2017313843A1 (en) * 2016-08-18 2019-03-07 Canopy Growth Corporation Plants and methods for increasing and decreasing synthesis of cannabinoids

Also Published As

Publication number Publication date
US10787675B2 (en) 2020-09-29
KR20200128050A (ko) 2020-11-11
US20200061138A1 (en) 2020-02-27
ES2929366T3 (es) 2022-11-28
AU2021202296A1 (en) 2021-05-13
JP2021113213A (ja) 2021-08-05
ES2926328T3 (es) 2022-10-25
EP3755318B1 (en) 2022-08-24
EP3884936B1 (en) 2022-10-12
PT3884936T (pt) 2022-10-25
US11629355B2 (en) 2023-04-18
PL3755318T3 (pl) 2022-12-19
US20200155629A1 (en) 2020-05-21
WO2019164689A1 (en) 2019-08-29
CA3091776C (en) 2021-12-28
HUE060229T2 (hu) 2023-02-28
PL3884936T3 (pl) 2022-12-05
JP7322353B2 (ja) 2023-08-08
US20230212597A1 (en) 2023-07-06
AU2019225717B2 (en) 2021-10-21
US11085047B2 (en) 2021-08-10
AU2019225717A1 (en) 2020-10-08
IL282342B (en) 2022-02-01
AU2021202296B2 (en) 2021-11-11
JP2021507937A (ja) 2021-02-25
CA3120993A1 (en) 2019-08-29
IL276518A (en) 2020-09-30
EP3755318A4 (en) 2021-04-14
EP3884936A1 (en) 2021-09-29
PT3755318T (pt) 2022-09-05
KR102332631B1 (ko) 2021-12-01
CA3120993C (en) 2022-06-21
CN112040942A (zh) 2020-12-04
KR20210055794A (ko) 2021-05-17
IL282342A (en) 2021-05-31
US20210380998A1 (en) 2021-12-09
CN113264914A (zh) 2021-08-17
KR102374793B1 (ko) 2022-03-17
JP7293561B2 (ja) 2023-06-20
EP3755318A1 (en) 2020-12-30
CA3091776A1 (en) 2019-08-29
IL276518B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL282342B (en) Genetically Modified Cannabis Sativa Plants and Modified Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders
ZA201900986B (en) Plants and methods for increasing and decreasing synthesis of cannabinoids
IL272627A (en) Terpene-enriched cannabinoid compositions and method of treatment
IL304526A (en) Production of compounds and preparations to inhibit the activity of shp2
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL284387A (en) A medical product that includes cannabinoid, terpene and herbs
EP3526319A4 (en) METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
EP3615657A4 (en) APPARATUS, METHODS AND COMPOSITION FOR THE SYNTHESIS OF CANNABINOID COMPOUNDS
EP3712130A4 (en) METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF
IL272321A (en) Methods and compositions for treating diseases of amyloid deposition
PT3611171T (pt) Método para a síntese de eliglustato e dos seus compostos intermédios
EP3681477A4 (en) IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES
EP3703706A4 (en) COMPOSITIONS AND METHOD FOR TREATING ACID-BASE DISORDERS
IL269390A (en) Preparations and methods for the treatment of parasitic diseases
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
PL3651586T3 (pl) Sposób izolacji białka z materiału roślinnego
IL269179A (en) Method for monitoring treatment of neuropsychiatric disorders
IL275653A (en) Purified cannabis extracts and methods for their preparation
IL259674B (en) Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases
IL292086A (en) Methods for the preparation of female cannabis sativa seed and preparations thereof
IL283201A (en) Process and compounds for preparation of cannabinoids
IL284112A (en) A method for extracting proteins from cannabis plant material
IL275941B (en) Physical means and methods for affecting cannabis plants
EP3621945A4 (en) STYLE DERIVATIVES FOR THE TREATMENT OF THE CNS AND OTHER DISEASES